INMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
INmune Bio Inc (INMB) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators are bearish, options data suggests a negative sentiment, and the financial performance shows significant losses. While there is a potential catalyst from the upcoming webinar on clinical trial results, the lack of strong trading signals and poor recent stock trends make it prudent to hold off on investing at this time.
The technical indicators are bearish. The MACD is below 0 and negatively expanding, the RSI is neutral at 22.603, and the moving averages indicate a downward trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.315), with resistance levels at R1: 1.669 and R2: 1.778.
The upcoming webinar on February 26, 2026, showcasing clinical trial results for CORDStrom, could provide a positive catalyst if the data is well-received.
The stock has a 50% chance of declining further (-2.12% in the next day, -3.14% in the next week, -3.1% in the next month). Additionally, the financial performance is weak, with significant YoY declines in net income (-46.48%) and EPS (-60.00%).
In Q3 2025, the company reported no revenue growth (0.00% YoY), a net income loss of -$6.47M (-46.48% YoY), and an EPS decline of -60.00% YoY. Gross margin remained at 100%, but this does not offset the weak overall financial performance.
No data on analyst ratings or price target changes is available. Wall Street sentiment is neutral with no significant hedge fund or insider trading activity.
